RxDoctor Payments Data

Amanda Trolinger, PA

Physician Assistant · Lone Tree, CONPI 1417267386

Payments from drug & device makers

$3,029in general payments, 2019–2025

Across 67 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
  • Amgen$403
  • AstraZeneca$247
  • Bayer$195
  • Boehringer Ingelheim$152
  • Nxstage Medical, Inc.$119
  • plus $713 from 12 others

What the payments were for

  • Consulting fees$1,20040%
  • Food & beverage$1,82960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,029 in reported general payments places this provider in the 90th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$13,545
Medicare patients
88
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol36$32,806
JardianceEmpagliflozin19$25,576
MounjaroTirzepatide19$18,324
Sevelamer Carbonate16$1,842
Duloxetine Hcl15$1,685
Furosemide107$1,285
Nifedipine ErNifedipine27$985
Lidocaine-PrilocaineLidocaine/Prilocaine30$944
Cinacalcet Hcl48$925
Amlodipine Besylate99$901
Losartan Potassium78$725
Calcitriol38$531
Tamsulosin Hcl21$504
Atorvastatin Calcium59$453
Hydralazine Hcl28$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$247$32,80636 claims
Boehringer IngelheimJardiance$152$25,57619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →